



(51) International Patent Classification:

C07K 19/00 (2006.01) *C12N 15/86* (2006.01)
C12N 15/62 (2006.01) *A61P 9/10* (2006.01)
C12N 15/63 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:

PCT/US2011/051858

(22) International Filing Date:

15 September 2011 (15.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US2011/028233 11 March 2011 (11.03.2011) US

(71) Applicant (for all designated States except US): **SYN-AGEVA BIOPHARMA CORP** [US/US]; Synageva Bio-Pharma Corp., 128 Spring Street, Suite 520, Lexington, Massachusetts 02421 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **QUINN, Anthony** [GB/US]; 107 Manet Road, Chestnut Hill, Massachusetts 02467 (US). **HARVEY, Alex J.** [US/US]; 106 Fox Trace, Athens, Georgia 30606 (US). **XIA, Zhinan** [US/US]; 29 Burke Lane, Wellesley, Massachusetts 02481 (US).

(74) Agents: **ZACHARAKIS, Maria, Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NPP1 FUSION PROTEINS




Fig. 19

(57) Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated therein, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.



Published:

— *with international search report (Art. 21(3))*